US Stock MarketDetailed Quotes

SWTX SpringWorks Therapeutics

Watchlist
  • 57.430
  • -1.160-1.98%
Close Feb 14 16:00 ET
  • 57.104
  • -0.327-0.57%
Post 19:59 ET
4.27BMarket Cap-14.76P/E (TTM)

About SpringWorks Therapeutics Company

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Company Profile

SymbolSWTX
Company NameSpringWorks Therapeutics
Listing DateSep 13, 2019
Issue Price18.00
Founded2017
CEOMr. Saqib Islam, J.D.
MarketNASDAQ
Employees305
Fiscal Year Ends12-31
Address100 Washington Boulevard
CityStamford
ProvinceConnecticut
CountryUnited States of America
Zip Code06902
Phone1-203-883-9490

Company Executives

  • Name
  • Position
  • Salary
  • Saqib Islam, J.D.
  • Director and Chief Executive Officer
  • 18.35M
  • Francis I. Perier, Jr
  • Chief Financial Officer
  • 3.74M
  • Michael Nofi
  • Chief Accounting Officer
  • --
  • Tai-An Lin
  • Chief Scientific Officer
  • --
  • Bhavesh Ashar, M.B.A.
  • Chief Commercial Officer
  • --
  • Daniel Pichl
  • Chief People Officer
  • --
  • Dr. Badreddin Edris, PhD
  • Chief Operating Officer
  • 6.64M
  • Dr. James Cassidy, M.D.,PhD
  • Chief Medical Officer
  • 4.31M
  • Daniel S. Lynch, M.B.A.
  • Chairman of the Board
  • 545.14K
  • Carlos Alban
  • Independent Director
  • 507.64K
  • Alan Fuhrman
  • Independent Director
  • 520.14K
  • Dr. Freda C. Lewis-Hall,M.D.
  • Independent Director
  • 508.45K
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • --
  • Dr. Julie Hambleton, M.D.
  • Independent Director
  • 520.14K
  • Herschel S. Weinstein, J.D.
  • General Counsel and Secretary
  • --

Trending Stocks

Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More